country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Cat. No.: HY-P99756

Copy Link Print Information

Biologically Validated

Nirsevimab

Name: Nirsevimab
Brand: MedChemExpress
SKU: HY-P99756
Price: 615.00 USD
Availability: InStock
Rating: 5 (4 reviews)

(Synonyms: MEDI8897)

4 Cited Publications

고객리뷰

Based on 4 publication(s) in Google Scholar

Nirsevimab (MEDI8897) is a recombinant monoclonal antibody against human respiratory syncytial virus (RSV). Nirsevimab has neutralizing activity against RSV A and RSV B viruses, with IC₅₀ values of 5.42 ng/mL and 9.71 ng/mL, respectively. Nirsevimab can be used for research on respiratory infections.

연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.

Purity : 98.63%
CAS No.: 1989556-22-0
분자량:146.31 kDa

보관:

Shipping with dry ice

Please store the product under the recommended conditions in the Certificate of Analysis.

Nirsevimab Chemical Structure

CAS No.: 1989556-22-0

사이즈

가격

재고

수량

Amount: USD 0.00

* 장바구니에 담기 전 물품의 수량을 선택해 주십시오.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- 제품 설명
- Isotype
- Recommend Isotype Controls
- Species Reactivity
- IC₅₀ & Target
- In Vitro
- In Vivo
- Clinical Trial
- Accession
- Conjugated
- Reconsititution
- Format
- 신청
- Verified Bioactivity
Chemical Information
Publications (4)
순도&문서
References
Calculators
Help & FAQs
Classifications
Bioz

Biological Activity

제품 설명

Isotype

Human IgG1 kappa

Recommend Isotype Controls

Human IgG1 kappa, Isotype Control

Species Reactivity

Human

IC₅₀ & Target

RSV-F

In Vitro

Nirsevimab can directly neutralize RSV virus and has fragment crystallizable (Fc) - mediated effector function, thereby preventing respiratory infections^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Nirsevimab (10-10000 μg/kg; i.m.) inhibits the antibody response in the respiratory mucosa of mice when pre-administered prior to RSV virus infection^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

3-week-old female BALB/c mice^[2].
Dosage:

10 μg/kg, 100 μg/kg, 1 mg/kg, 10 mg/kg
Administration:

Intramuscular injection (i.m.); administer medication 24 hours prior to RSV virus exposure
Result:

Inhibited the secretion of sIgA, mucosal IgA, and mucosal IgG in the offspring subsequent to the initial RSV infection.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991			2011-05	PHASE1

Accession

A0A0X8XRK2

Conjugated

Unconjugated

Reconsititution

The product can be reconstituted/diluted with sterile PBS or saline.

Format

Human IgG1 kappa

신청

ELISA, FACS, Functional assay

Verified Bioactivity

Immobilized Fusion glycoprotein F0/F Protein, HRSV (sf9, His, HY-P75182) can bind Nirsevimab. The EC₅₀ for this effect is 44 ng/mL.

Chemical Information

CAS No. 1989556-22-0
Appearance Liquid
분자량 146.31 kDa
Color Colorless to light yellow
SMILES

[Nirsevimab]
Synonyms

MEDI8897
선적

Shipping with dry ice.
Formulation

Please refer to the lot-specific COA for specific buffer information.
보관

Please store the product under the recommended conditions in the Certificate of Analysis.

Publications (4)

All Bio/Physico-chemical Assay

Sort by:

Journal Impact Factor

Virol J

2026 Sep 29;23(1):226. PMID: 42811372
J Med Virol

Development of a HEp2-CDX Mouse Model With Sustained High RSV Viral Loads for Robust Antiviral Therapeutic Evaluation. [Abstract]

2025 Sep;97(9):e70601. PMID: 40947663
J Immunol Methods

2026 Sep 27:114127. PMID: 42802006
bioRxiv

2026 Feb 4.

Nirsevimab purchased from MedChemExpress. Usage Cited in: bioRxiv. 2026 Feb 4.

All MARMs could be rescued by at least one other mAb. Three RSM01 MARMs (RSM-1 to RSM-3) could still be neutralised by nirsevimab and clesrovimab.

Nirsevimab purchased from MedChemExpress. Usage Cited in: bioRxiv. 2026 Feb 4.

RSV-B isolates displayed 17 highly variable positions, two of which are located in overlapping RSM01/nirsevimab binding sites.

순도&문서

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (261 KB)
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Inhibitory Antibodies User Guide (603 KB)

References

[1]. Brady T, et al. Fc-mediated functions of nirsevimab complement direct respiratory syncytial virus neutralization but are not required for optimal prophylactic protection. Front Immunol. 2023 Oct 11;14:1283120. [Content Brief]

[2]. Ma J, et. Exacerbated lung inflammation in offspring with high maternal antibody levels following secondary RSV exposure. Front Immunol. 2024 Apr 30;15:1377374. [Content Brief]

Calculators

몰농도 계산기

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

농도 희석 계산기

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Bioz

Keywords

Nirsevimab

4 Cited Publications

100 mg 견적 받기

Subscribe to the

MedChemExpress

Newsletter

MOQ

Minimum order quantity

100 mg

견적 받기 해외재고보유

Other size

견적 받기

Amount: USD 0.00

Biological Activity
- 제품 설명
- Isotype
- Recommend Isotype Controls
- Species Reactivity
- IC₅₀ & Target
- In Vitro
- In Vivo
- Clinical Trial
- Accession
- Conjugated
- Reconsititution
- Format
- 신청
- Biological Activity
Chemical Information
Publications (4)
순도&문서
References

1/16

Human IgG1 kappa
1/16

Immobilized Fusion glycoprotein F0/F Protein, HRSV (sf9, His, HY-P75182) can bind Nirsevimab. The EC₅₀ for this effect is 44 ng/mL.
1/16

Nirsevimab purchased from MedChemExpress. Usage Cited in: bioRxiv. 2026 Feb 4.

Customer Validation
All MARMs could be rescued by at least one other mAb. Three RSM01 MARMs (RSM-1 to RSM-3) could still be neutralised by nirsevimab and clesrovimab.
1/16

Nirsevimab purchased from MedChemExpress. Usage Cited in: bioRxiv. 2026 Feb 4.

Customer Validation
RSV-B isolates displayed 17 highly variable positions, two of which are located in overlapping RSM01/nirsevimab binding sites.
1/16

상품명:
Cat. No.:
수량:
MCE Japan Authorized Agent:

상품명:
CAS No.:
Species:
Purity:
수량:

Nirsevimab

Publications Citing Use of MedChemExpress (MCE) Nirsevimab